<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307149</url>
  </required_header>
  <id_info>
    <org_study_id>VLA-013</org_study_id>
    <secondary_id>PHS IRB: 14-241</secondary_id>
    <nct_id>NCT02307149</nct_id>
  </id_info>
  <brief_title>Intratumoral CAVATAK (CVA21) and Ipilimumab in Patients With Advanced Melanoma (VLA-013 MITCI)</brief_title>
  <acronym>MITCI</acronym>
  <official_title>A PHASE 1b STUDY OF INTRATUMORAL CAVATAK® (COXSACKIEVIRUS A21, CVA21) AND IPILIMUMAB IN PATIENTS WITH ADVANCED MELANOMA (VLA-013 MITCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Viralytics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Providence Health &amp; Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Viralytics</source>
  <brief_summary>
    <textblock>
      Open label, single arm study of intratumoral CVA21 and ipilimumab in advanced melanoma
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:

      To evaluate the safety and efficacy of CAVATAK (CVA21) administered intratumorally in
      combination with the approved dose and schedule of ipilimumab. Of particular interest is to
      estimate the overall response rate (ORR) in the subgroup of subjects with unresectable or
      metastatic stage III B/C or IV melanoma who have progressed on a single prior anti-PD-1
      therapy.

      Secondary Objectives:

        1. Assess the clinical efficacy of ipilimumab in combination with intratumoral CVA21 in
           terms of:

             -  Immune-related progression-free survival (irPFS) at 6 and 12 months,

             -  Durable response rate (DRR),

             -  1-year survival,

             -  Overall survival (OS), and

             -  Quality of life.

        2. Assess the response of injected and non-injected melanoma lesions after CVA21 and
           ipilimumab.

        3. Assess the time to initial response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
    <time_frame>106 days</time_frame>
    <description>Best response of complete response (CR) or partial response (PR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DRR</measure>
    <time_frame>lasting 26 weeks or longer</time_frame>
    <description>Durable Response Rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>At 6 and 12 months</time_frame>
    <description>Progression-Free Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>Through study completion, an average of 2 years</time_frame>
    <description>Overall</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">59</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>CAVATAK and ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CAVATAK intratumoral injection up to a total dose of 3 x 10⁸ TCID50 and ipilimumab intravenously at the recommended dose of 3 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CAVATAK</intervention_name>
    <description>CAVATAK is a preparation of CVA21</description>
    <arm_group_label>CAVATAK and ipilimumab</arm_group_label>
    <other_name>Coxsackievirus A21, CVA21</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma</description>
    <arm_group_label>CAVATAK and ipilimumab</arm_group_label>
    <other_name>Yervoy®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with unresectable or metastatic stage III B/C or IV melanoma. Patients
             enrolled under this version of the protocol must also have progressed on prior
             anti-PD-1 therapy, according to RECIST 1.1 criteria. Patients who progressed within 3
             months of treatment start are excluded.

          2. Patients must have at least one cutaneous or subcutaneous tumor, measuring 0.5 to 5.0
             cm in the longest diameter, or a palpable lymph node. At least one tumor must qualify
             as an index lesion that can be accurately and reproducibly measured in two dimensions
             for which the longest diameter is .10 mm (.15 mm in short axis diameter [SAD] for
             lymph nodes), and be amenable to intratumoral injection.

          3. Histological confirmation of melanoma will be required by previous biopsy or cytology.

          4. Patients who have received prior ipilimumab treatment for metastatic melanoma are not
             eligible.

          5. Patients with ≤ 3 visceral metastases (excluding pulmonary lesions), with no lesions
             &gt;3.0 cm. Patients with substantial tumor burden of non-measurable disease may not be
             good candidates for an immunotherapy and should be discussed with the Medical Monitor.

        7. ECOG performance status of 0-1.

        Key Exclusion Criteria:

          1. Patients with tumors to be injected lying close to an airway, major blood vessel or
             spinal cord that, in the opinion of the Investigator, could cause occlusion or
             compression in the case of tumor swelling or erosion into a major vessel in the case
             of necrosis. Patients with lesions in mucosal areas (vulvar, anus, oral cavity, etc.),
             are eligible, as long as the subject has at least one lesion suitable for injection;
             consult Medical Monitor for confirmation.

          2. Patients with active, known or suspected autoimmune disease except for autoimmune
             thyroiditis or vitiligo. Thyroiditis patients must be asymptomatic, on adequate
             thyroid replacement and have normal thyroid function tests.

          3. Patients with active colitis or immune-mediated colitis that has not resolved to grade
             1 or less.

          4. Patients with untreated brain metastases. Patients with treated brain metastases who
             are off corticosteroids for at least two weeks and who demonstrate control of brain
             metastases with follow-up imaging 4 or more weeks after initial therapy are eligible.

          5. Patients previously treated with CVA21.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brendan Curti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Health &amp; Services</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leslie Guerreiro</last_name>
    <email>leslie.guerreiro@viralytics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope National Medical Center,</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Williams</last_name>
      <phone>626-218-0572</phone>
    </contact>
    <investigator>
      <last_name>Kim Margolin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hailey Tipton</last_name>
      <phone>858-822-0201</phone>
    </contact>
    <investigator>
      <last_name>Gregory Daniels, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Wayne Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Garver</last_name>
      <phone>310-582-7456</phone>
    </contact>
    <investigator>
      <last_name>Steven O'Day, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Salvador</last_name>
      <phone>305-243-7358</phone>
    </contact>
    <investigator>
      <last_name>Lynn Feun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Health, SC</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Tolzien</last_name>
      <phone>847-410-0658</phone>
    </contact>
    <investigator>
      <last_name>Jon Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosemary Boyle</last_name>
      <phone>617-724-3173</phone>
    </contact>
    <investigator>
      <last_name>Ryan Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Maattala</last_name>
      <phone>617-632-3992</phone>
    </contact>
    <investigator>
      <last_name>Ryan Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Melanoma Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maureen Nowakowski</last_name>
      <phone>973-971-6298</phone>
    </contact>
    <investigator>
      <last_name>Eric Whitman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Fountain</last_name>
      <phone>503-215-2691</phone>
    </contact>
    <investigator>
      <last_name>Brendan D Curti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Willis</last_name>
      <phone>801-587-4767</phone>
    </contact>
    <investigator>
      <last_name>Robert Andtbacka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>ipilimumab</keyword>
  <keyword>coxsackievirus A21</keyword>
  <keyword>CAVATAK</keyword>
  <keyword>CVA21</keyword>
  <keyword>checkpoint inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

